Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
49.23
-0.14 (-0.28%)
At close: Feb 18, 2026, 4:00 PM EST
49.20
-0.03 (-0.06%)
After-hours: Feb 18, 2026, 6:48 PM EST
Novo Nordisk Revenue
In the year 2025, Novo Nordisk had annual revenue of 309.06B DKK with 6.43% growth. Novo Nordisk had revenue of 79.14B in the quarter ending December 31, 2025, a decrease of -7.63%.
Revenue (ttm)
309.06B DKK
Revenue Growth
+6.43%
P/S Ratio
4.50
Revenue / Employee
4,446,644 DKK
Employees
69,505
Market Cap
218.82B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | 3.09B | 7.97% |
| Dec 31, 2006 | 38.74B | 4.98B | 14.76% |
| Dec 31, 2005 | 33.76B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Bristol-Myers Squibb Company | 48.19B |
NVO News
- 1 day ago - Novo Nordisk: The Possible Upside - Seeking Alpha
- 1 day ago - Novo Nordisk's Wegovy Weight Loss Shot Approved at Higher Dose in EU - WSJ
- 1 day ago - EU approves higher dose of Novo's Wegovy - Reuters
- 1 day ago - Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average - GlobeNewsWire
- 2 days ago - Novo Nordisk A/S - share repurchase programme - GlobeNewsWire
- 5 days ago - Novo's Wegovy pill tracks over 38,000 prescriptions in fifth week - Reuters
- 5 days ago - Prices, pipelines and patent cliffs: Inside pharma's big reset - CNBC
- 5 days ago - US could take action including fines against Hims after brief Wegovy copy launch - Reuters